Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mesoblast gets EU green light for cardiovascular stem cell trial

This article was originally published in Clinica

Executive Summary

Australia's Mesoblast has got the go-ahead to start a European Phase IIb trial of its Revascor cardiovascular stem cell therapy. The study, called AMICI, will evaluate the off-the-shelf therapy in 225 heart attack patients in countries including the UK, the Netherlands and Belgium. Mesoblast plans to later expand the trial to include patients in other European countries, as well as the US and Australia.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT097838

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel